Literature DB >> 28850676

Addressing Pharmaceutical Injuries: The US Landscape.

Cecilia Bakker1, Nicholaas Honig2.   

Abstract

The legal landscape for addressing an injury related to the use of a pharmaceutical product varies from country to country. Approximately 10 countries have adopted some form of no-fault compensation, in which an individual must establish that they sustained an injury caused by the medicine, but need not demonstrate that the manufacturer acted negligently in order to recover. This commentary compares and contrasts the approach taken in Japan with that in the United States.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2017        PMID: 28850676     DOI: 10.1002/cpt.774

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  1 in total

1.  Process Improvement for Maximized Therapeutic Innovation Outcome.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Pharmacol Ther       Date:  2018-01       Impact factor: 6.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.